Hypoxia-Inducible Factor-1α-Activated Protein Switch Based on Allosteric Self-Splicing Reduces Nonspecific...

Area of Science:

• Biotechnology
• Molecular Biology
• Oncology

Background:

• Protein-based therapeutics face challenges like poor penetration, toxicity, and short half-life.
• Current targeted therapies using cell surface receptors still cause off-target toxicity due to receptor expression in normal cells.

Purpose of the Study:

• To design an allosteric-regulated protein switch for enhanced tumor cell targeting and reduced nonspecific toxicity.
• To develop a novel strategy for activating therapeutic functions specifically within cancer cells.

Main Methods:

• Engineered an allosteric-regulated protein switch utilizing self-splicing elements.
• Designed the system to interact with cancer markers and target hypoxia-induced factor 1-alpha (HIF-1α) in tumor cells.
• Achieved cytoplasmic reorganization of engineered immunotoxins within tumor cells.

Main Results:

• The protein switch selectively activated in hypoxic cancer cells, leading to splicing product presence only in these cells.
• Engineered immunotoxins were specifically localized and activated within tumor cells.
• Demonstrated significant reduction in nonspecific toxicity to normal cells.

Conclusions:

• The allosteric-regulated protein switch offers a promising platform for targeted tumor therapy.
• This approach provides a universal strategy to combine therapeutic function activation with specific cancer markers.
• The allosteric self-splicing element effectively minimizes the cytotoxicity of therapeutic proteins.